PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth while RVPH is at 82.55%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-26.14%
Negative operating income growth while RVPH is at 82.55%. Joel Greenblatt would press for urgent turnaround measures.
-26.43%
Negative net income growth while RVPH stands at 232.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-26.52%
Negative EPS growth while RVPH is at 224.74%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-26.52%
Negative diluted EPS growth while RVPH is at 224.74%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x RVPH's 6.23%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.09%
Diluted share reduction more than 1.5x RVPH's 6.23%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while RVPH is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.72%
Negative FCF growth while RVPH is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
12.78%
OCF/share CAGR of 12.78% while RVPH is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
32.48%
3Y OCF/share CAGR of 32.48% while RVPH is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-18544.23%
Negative 10Y net income/share CAGR while RVPH is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
7.55%
Net income/share CAGR of 7.55% while RVPH is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
44.34%
3Y net income/share CAGR of 44.34% while RVPH is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
1862.49%
Equity/share CAGR of 1862.49% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
309.42%
Equity/share CAGR of 309.42% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-81.93%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Negative asset growth while RVPH invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-33.19%
We have a declining book value while RVPH shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth of 26.95% while RVPH is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
24.63%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.